Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Tavernier (Manchester, United Kingdom), L. Elsey (Manchester, United Kingdom), N. Bhola (Manchester, United Kingdom), L. Holmes (Manchester, United Kingdom), D. Allen (Manchester, United Kingdom), R. Niven (Manchester, United Kingdom). Prevalence of adrenal insufficiency in patients started on Mepolizumab for severe eosinophilic asthma.. 2512

Member's Comments

No comment yet.

Related content which might interest you: Experience with Mepolizumab in a cohort of patients with eosinophilic severe persistent asthma Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Mepolizumab efficacy in patients with severe eosinophilic asthma and bronchiectasis Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Characterisation of severe eosinophilic asthma patients who failed Mepolizumab therapy Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Rapid Benralizumab effectiveness in patients with severe eosinophilic asthma and bronchiectasis Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Clinical characteristics and corticosteroid treatment of acute eosinophilic pneumonia Source: Eur Respir J 2013; 41: 402-409 Year: 2013 Late-onset persistent eosinophilic severe asthma Source: International Congress 2015 – Severe asthma phenotyping Year: 2015 The characteristics of treatment failure with omalizumab in patients with severe asthma: The impact of eosinophilic complication Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Effect of anti-IL5 treatment on symptoms of chronic rhinosinusitis, otitis and hearing loss in patients with severe eosinophilic asthma Source: International Congress 2019 – Clinical approach to asthma management Year: 2019 Effect of ABPA treatment in severe asthma patients with acute and relapsed disease Source: Virtual Congress 2020 – Advances in asthma treatment Year: 2020 Prevalence and clinical characteristics of blood eosinophilia in patients with acute exacerbation of chronic obstructive pulmonary disease in China Source: International Congress 2017 – COPD biomarkers Year: 2017 Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma Source: ERJ Open Res, 7 (4) 00465-2021; 10.1183/23120541.00465-2021 Year: 2021 Impact of anemia in patients admitted due to a chronic obstructive pulmonary disease (COPD) exacerbation. Source: Virtual Congress 2021 – Prediction of exacerbations in patients with COPD Year: 2021 Combined therapy of severe osteoporosis for patients with bronchial asthma Source: Eur Respir J 2001; 18: Suppl. 33, 47s Year: 2001 Localization of respiratory viral antigens in patients with exacerbations of non allergic late-onset asthma and chronic obstructive pulmonary disease Source: Eur Respir J 2004; 24: Suppl. 48, 411s Year: 2004 Anti-IL5 therapy could prevent lung function decline in severe eosinophilic asthma: data from the belgian severe asthma registry Source: Virtual Congress 2021 – Clinical features and new biomarkers of asthma, COPD and chronic cough Year: 2021 Prevalence of nasal symptoms and their relation to self-reported asthma and chronic bronchitis/emphysema Source: Eur Respir J 2001; 17: 596-603 Year: 2001 Benralizumab for severe asthma associated with extra-airway eosinophilic diseases Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Frequency of depressive syndrome in patients with bronchial asthma and chronic obstructive pulmonary disease Source: Virtual Congress 2021 – Pulmonary rehabilitation in clinical conditions Year: 2021 Predictors of severe exacerbations in patients with moderate and severe asthma Source: International Congress 2018 – Determinants and monitoring of asthma control Year: 2018 Clinical response to mepolizumab in patients with severe eosinophilic asthma Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019